Prelude Therapeutics Incorporated

NasdaqGS:PRLD 株式レポート

時価総額:US$52.2m

Prelude Therapeutics マネジメント

マネジメント 基準チェック /34

Prelude Therapeuticsの CEO はKris Vaddiで、 Feb2016年に任命され、 の在任期間は 8.75年です。 の年間総報酬は$ 2.64Mで、 21.7%給与と78.3%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の3.93%を直接所有しており、その価値は$ 2.05M 。経営陣と取締役会の平均在任期間はそれぞれ2.9年と4.5年です。

主要情報

Kris Vaddi

最高経営責任者

US$2.6m

報酬総額

CEO給与比率21.7%
CEO在任期間8.8yrs
CEOの所有権3.9%
経営陣の平均在職期間2.9yrs
取締役会の平均在任期間4.5yrs

経営陣の近況

Recent updates

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Sep 16
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 09
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data

Feb 03

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Sep 17
Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 28
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Jan 28
Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely

Oct 27
We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely

Prelude wins FDA clearance to start Phase 1 trial for cancer candidate

Oct 18

Prelude downgraded at Morgan Stanley ahead of key update

Sep 09

We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Jun 28
We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Mar 14
Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Dec 14
We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Jul 05
Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

Feb 16
What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

Prelude Therapeutics prices $150M share offering

Jan 07

Prelude Therapeutics readies public offering

Jan 04

Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares

Dec 25
Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares

CEO報酬分析

Prelude Therapeutics の収益と比較して、Kris Vaddi の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$132m

Jun 30 2024n/an/a

-US$130m

Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$3mUS$573k

-US$122m

Sep 30 2023n/an/a

-US$117m

Jun 30 2023n/an/a

-US$117m

Mar 31 2023n/an/a

-US$114m

Dec 31 2022US$3mUS$558k

-US$115m

Sep 30 2022n/an/a

-US$120m

Jun 30 2022n/an/a

-US$120m

Mar 31 2022n/an/a

-US$120m

Dec 31 2021US$7mUS$544k

-US$112m

Sep 30 2021n/an/a

-US$98m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$69m

Dec 31 2020US$12mUS$417k

-US$57m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$38m

Mar 31 2020n/an/a

-US$32m

Dec 31 2019US$2mUS$315k

-US$28m

報酬と市場: Krisの 総報酬 ($USD 2.64M ) は、 US市場 ($USD 649.63K ) の同規模の企業の平均を上回っています。

報酬と収益: Krisの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Kris Vaddi (58 yo)

8.8yrs

在職期間

US$2,641,789

報酬

Dr. Krishna Vaddi, D.V.M., Ph D., also known as Kris, founded Prelude Therapeutics Incorporated and serves as its Chief Executive Officer and Director from February 2016. He has been its Chief Executive Of...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Krishna Vaddi
Founder8.8yrsUS$2.64m3.93%
$ 2.1m
Edna Huang
President & Chief Medical Officer2.6yrsUS$1.65m0.12%
$ 60.1k
Bryant Lim
Interim CFO1.8yrsUS$1.67m0.0044%
$ 2.3k
Aimee Crombie
Senior VP and Head of Strategic Planning & Operations2.8yrsデータなしデータなし
Madhu Pudipeddi
Senior Vice President of Technical Operations3.8yrsデータなしデータなし
Peggy Scherle
Chief Scientific Officer6.6yrsUS$1.63m0.33%
$ 171.4k
Lindsey Trickett
Vice President of Investor Relationsno dataデータなしデータなし
Michele Porreca
Chief People Officer3.4yrsデータなしデータなし
Andrew Combs
Executive VP & Chief Chemistry Officer5.6yrsUS$2.63m0.57%
$ 296.0k
Naveen Babbar
Senior Vice President of Translation Medicine2.9yrsデータなしデータなし
William Novotny
Senior Vice President of Clinical Development2.2yrsデータなしデータなし
Wan-Jen Hong
Senior Vice President of Clinical Development2.1yrsデータなしデータなし

2.9yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: PRLDの経営陣は 経験豊富 であると考えられます ( 2.9年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Krishna Vaddi
Founder8.8yrsUS$2.64m3.93%
$ 2.1m
Julian Baker
Independent Director3.8yrsUS$140.03k0%
$ 0
Paul Friedman
Independent Chairman of the Board8.3yrsUS$161.03k0.91%
$ 474.4k
Martin Babler
Independent Director3.3yrsUS$134.53k0%
$ 0
David Bonita
Independent Director8.3yrsUS$144.53k0%
$ 0
Mardi Dier
Independent Director4.3yrsUS$147.03k0.018%
$ 9.5k
Victor Sandor
Independent Director4.5yrsUS$131.03k0%
$ 0

4.5yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: PRLDの 取締役会経験豊富 であると考えられます ( 4.5年の平均在任期間)。